85% of Atypical Alzheimer’s Patients May Not Qualify for Treatment
Researchers found 70% to 85% of biomarker-confirmed atypical Alzheimer’s patients would miss early anti-amyloid treatment under current trial criteria.
3 Articles
3 Articles
85% of Atypical Alzheimer’s Patients May Not Qualify for Treatment
Current treatment criteria may exclude many people with atypical Alzheimer’s disease even when they remain in relatively early stages. For some people with Alzheimer’s disease, memory loss is not the first warning sign. Problems with vision, language, planning, or movement can appear earlier, and new research suggests that these less typical symptoms may prevent many [...]
A recent study revealed that up to 85% of patients with atypical Alzheimer's may not qualify for anti-amyloid therapies, even in the early stages of the disease. The research, published in the journal Neurology, highlights the need to review the treatment criteria currently used. Treatment criteria exclude atypical cases. The eligibility criteria for anti-amyloid treatments, such as lecanemab and donanemab, may not adequately consider patients w…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
